Transactions
5
Insider / Moderna, Inc.
NABEL ELIZABETH G
Director at Moderna, Inc.
- Company
- Moderna, Inc.
- First filing on record
- April 29, 2026
- Latest trade on record
- May 6, 2026
- SEC filings
- EDGAR ↗
NABEL ELIZABETH G, Director at Moderna, Inc., has disclosed 5 transactions in MRNA, MDT since April 29, 2026: 0 purchases (0 open-market buys) and 1 sale, worth about $17K at the reported prices. The latest was filed May 8, 2026, 2 days after the trade.
Open-market buys
0
Sales
1
Avg. disclosure lag
2.6d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months NABEL ELIZABETH G made no purchases and 1 sale worth $17K, plus 4 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
NABEL ELIZABETH G has traded 1 stock on record; the largest by dollars is MDT.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 3 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 2 | 10,482 | — |
| M | Option exercise or conversion | 2 | 32,466 | — |
| F | Shares withheld for tax | 1 | 207 | $17K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 5 | 0 | 1 · $17K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | Other A | May 6, 2026 | May 8, 2026 | 2d | 8,371 | — | — | derivative | Form 4 ↗ | |
| MRNA | Option / conversion M | April 30, 2026 | May 4, 2026 | 4d | 16,233 | — | — | derivative | Form 4 ↗ | |
| MRNA | Option / conversion M | April 30, 2026 | May 4, 2026 | 4d | 16,233 | — | — | Form 4 ↗ | ||
| MDT | Sell F | April 28, 2026 | April 29, 2026 | 1d | 207 | $82 | $17K | Form 4 ↗ | ||
| MDT | Other A | April 27, 2026 | April 29, 2026 | 2d | 2,111 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 8, 2026 | Form 4 | 0001682852-26-000091 | 1 | published | EDGAR ↗ |
| May 4, 2026 | Form 4 | 0001682852-26-000066 | 2 | published | EDGAR ↗ |
| April 29, 2026 | Form 4 | 0001619929-26-000002 | 2 | published | EDGAR ↗ |
Other insiders at Moderna, Inc.
- Hoge Stephen President 76 rows
- Mock James M Chief Financial Officer 68 rows
- Klinger Shannon Thyme Chief Legal Officer 64 rows
- KIIL HARRY SKIP EVP & President Cardiovascular 22 rows
- ARNOLD CRAIG Director 17 rows
- Bancel Stephane Chief Executive Officer 15 rows
- Blomquist Denise L. Chief Accounting Officer 13 rows
- DONNELLY SCOTT C Director 11 rows
- Marinaro Michael EVP, Pres MedSurg and Americas 11 rows
- Martha Geoffrey Chairman and CEO 11 rows
Everyone on file, with contracts and lobbying under the company's name: Moderna, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 3 | 5 | April 29, 2026 | May 8, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.